Neogenomics Laboratories

NeoGenomics News

Looking for NeoAccess? Go here to log in


Test Updates

PD-L1 22C3 Reporting for the NeoTYPE® Esophageal Profile

To accommodate PD-L1 22C3 scoring/reporting for both ESCC (currently tested in the NeoTYPE® Esophageal Profile) and Gastric/GEA (to be added to the profile due to recent FDA approval), the following changes will be in place beginning on Monday, June 3rd:

  • PD-L1 22C3 testing for the NeoTYPE® Esophageal Profile will be updated to report without specifying “positive” or “negative”.
  • The Immuno-Oncology Biomarkers section within the Results Summary will display the %TPS and CPS for PD-L1 22C3 along with a note to “see table below for disease specific interpretation.”
  • The Profile Results Detail will include the Histology Testing Detail with the PD-L1 22C3 %TPS and CPS scoring as well as a disease specific scoring table that contains the test cut-off associated with the approved cancer type/therapeutic.

PD-L1 22C3 naming and scoring table updates for Neo Comprehensive™- Solid Tumor

Clients ordering PD-L1 22C3 with Neo Comprehensive™- Solid Tumor will notice a couple of updates beginning Monday, June 3rd:

  • The naming convention for PD-L1 will be simplified from “PD-L1 22C3 (Neo Comprehensive™)” to “PD-L1 22C3". 
  • The disease specific interpretation table will be updated to include the Gastric/GEA therapeutic and test cut-off information (see NeoTYPE® Esophageal update above for table details).

Special Updates


NeoGenomics to exhibit at the 2024 ASCO® Annual Meeting

The countdown has begun for the 2024 ASCO Annual Meeting! NeoGenomics will be exhibiting at booth #31093 where we will be highlighting our Lung Cancer and Heme Solutions, as well as holding discussions around partnering with Neo to support innovative testing and data solutions.

We are incredibly excited to be hosting a unique photo opportunity, where you can take a fun photo for a special cause. For each photo shared on social media with #NeoGivesBack, we will be donating $25* toward Conquer Cancer®, the ASCO Foundation.

If you plan on attending, please be sure to stop by and say hello. We would love to meet you. Let us know you're coming.


* Up to $10,000


Interface Updates

For a complete list of interface-related test changes, click here for a downloadable document to view the impacted interface test codes.